University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test

SAN DIEGO and ANN ARBOR, Mich., July 13 /PRNewswire-FirstCall/ -- Results from a study published by the University of Michigan have shown that as many as 15% of women in the study group determined to be negative for the presence of human papillomavirus (HPV) in the cervix, via ...

CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients

ATLANTA, May 27 /PRNewswire-USNewswire/ -- The Centers for Disease Control and Prevention (CDC) Foundation, CDC and Amgen today announced the launch of a three-year campaign to reduce infections among cancer patients. The campaign will provide resources and educational tools to help patients, fami...

Cystic Fibrosis - Orphan Drug Designation for Innovative Treatment Against Lung Infections by Axentis Pharma AG

ZURICH, Switzerland, April 30 /PRNewswire/ -- An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received orphan drug designation in the US. Axentis Pharma of Zurich, Switzerland announced today that this sought-after designation has been granted to...

Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients

ASHBURN, Va., March 19 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the second of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R)...

Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients

ASHBURN, Va., March 16 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the first of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) ...

Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)

PARIS, March 3 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced injectable antibacterial, which combines...

10-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs

ROCKVILLE, Md., Feb. 19 /PRNewswire-USNewswire/ -- Hospital associations in 10 states have been selected to participate in a program to test methods of reducing central-line associated blood stream infections in hospital intensive care units (ICUs), according to HHS' Agency for Healthcare Research...

Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)

CHICAGO, June 25 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS ), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases, today announced that...

Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients

SAN DIEGO, June 25 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced that it has initiated a Phase 2 clinical study with MP-376 for the treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis. MP-376 is Mpex's proprietary aer...

Cardiovascular Researchers Use MEDIHONEY(TM) on Sternal Infections Following Open-Heart Procedures

Full Clinical Study Initiated Following Success with 8 Patients PRINCETON, N.J., May 13 /PRNewswire-FirstCall/ -- Derma Sciences (OTC Bulletin Board: DSCI), a provider of advanced wound care products, today announced that a group of cardiovascular and thoracic surgeons from the University ...

Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients

ASHBURN, Va., Jan. 2 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the first of two phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the pre...

APIC Launches 'Targeting Zero' Initiative to Eradicate C. Difficile and Infections Deemed Preventable By CMS

Campaign will Arm Infection Prevention Professionals With Guidelines and Tools WASHINGTON, Dec. 18 /PRNewswire-USNewswire/ -- The Association for Professionals in Infection Control and Epidemiology (APIC) today announced a series of new educational initiatives aimed at eliminati...

Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals

MRSA Scorecard Provides Hospital-Wide View of MRSA Infections DUBLIN, Ohio, Oct. 30 /PRNewswire-FirstCall/ -- Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, today announced a new service to help hospitals combat methici...

New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects

ANN ARBOR, Mich., Sept. 19 /PRNewswire/ -- A new topical lotion that penetrates the skin deeply enough to target and eliminate serious skin infections, but without being systemically absorbed, has shown a high degree of safety and tolerability in patients with onychomycosis, or toenail fungus,...

DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux

- Need for Antibiotics Eliminated in 87 Percent of Patients, New Study Finds - PRINCETON, N.J., Aug. 7 /PRNewswire/ -- DEFLUX(R) (non-animal stabilized hyaluronic acid/dextranomer gel), for the treatment of vesicoureteral reflux (VUR) in children, reduced the in...

Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections

SAN DIEGO, June 30 /PRNewswire/ -- Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo act...

Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections

Second Generation Oxazolidinone Demonstrates Safety and Efficacy with Once-Daily, 200 milligrams (mg) Dosing over Five to Seven Days of Treatment SAN DIEGO, June 8 /PRNewswire/ -- Trius Therapeutics, Inc. today announced results from its Phase 2 clinical trial evaluating the safety and effic...

Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections

A Drug's Activity Against Anaerobes is the Leading Attribute in Antibiotic Selection, According to a New Report from AMR and Decision Resources MALVERN, Pa. and WALTHAM, Mass. , May 27 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that surveyed physicians will...

Obesity Associated With Higher Risk for Urinary Tract Infections

LINTHICUM, Md., April 27 /PRNewswire-USNewswire/ -- As body mass increases, so does a patient's risk of urinary tract infection (UTI), according to Baltimore researchers. A new study, presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA), assesses and stra...

Hospital Care Varies Greatly for Children with Urinary Tract Infections

-Standardizing Care May Improve Quality, Reduce Hospital Stays- PHILADELPHIA, April 21 /PRNewswire-USNewswire/ -- More than 45,000 infants and children in the United States are hospitalized each year for urinary tract infections, but a new study reveals significant variability across hospital...

Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections

BIRMINGHAM, Ala., Feb. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that the full data set from an exploratory Phase 2 study of peramivir in patients hospitalized for influenza was presented by the study's Principal Investigator, Dr. Michael G. Ison, Assi...

Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections

180 Patient Trial of 2nd Generation Oxazolidinone Enrolls in Four Months SAN DIEGO, Jan. 26 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the completion of enrollment in its randomized, double-blind Phase 2 clinical trial testing the oral dosage form of torezolid (also known as TR...

Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections

PARIS, November 12 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced injectable antibacterial, which comb...

Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections

Data to be presented at annual ICAAC/IDSA meeting in Washington, D.C. WASHINGTON, Oct. 28 /PRNewswire/ -- Scientists at NanoBio Corporation have demonstrated for the first time in humans that a novel topical treatment for cold sores (herpes labialis), NB-001, speeds healing of lesions as effe...

Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections

Iclaprim also achieved high eradication rates for the most common pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) REINACH, Switzerland, Oct. 26 /PRNewswire-FirstCall/ -- Arpida (SWX: ARPN) today presented the combined results from two pivotal Phase III clinical tri...

Keraderm to Release $100 Phototherapy Treatment for Fungal Nail Infections

HAMPTON, Va., Sept. 17 /PRNewswire/ -- Keraderm, a leader in the development of phototherapy treatments for infections, plans to introduce a $100 phototherapy treatment for fungal nail infections (onychomycosis) in 2009 upon completion of their current pivotal trials and pending marketing clea...

Nation's Foremost Health Care Leaders Kick Off Summit Focused on Zero-Tolerance Approach to Hospital-Acquired Infections

Summit attendees say HAIs are most difficult preventable medical conditions to address; Hospitals must improve infection prevention awareness, education and training to reduce HAIs WASHINGTON, Sept. 9 /PRNewswire-FirstCall/ -- As health care providers brace for an October deadl...

Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections

ZURICH, Switzerland, September 4 /PRNewswire/ -- Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an establis...

Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections

- Company Reports Favorable Phase 1 RX-3341 Results - NEW HAVEN, Conn., July 15 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant i...

Study Shows Use of AdvanDx's PNA FISH(TM) Test was Associated with an 82% Reduction in Intensive Care Unit Mortality Rates from Staphylococcus aureus Bloodstream Infections

WOBURN, Mass., July 15 /PRNewswire/ -- AdvanDx today announced that a new study shows use of AdvanDx's PNA FISH(TM) test was associated with an 82% reduction in mortality rates from S. aureus bloodstream infections in the intensive care unit (ICU), a 53% reduction in overall mortality from sta...

BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections

BD GeneOhm(TM) Cdiff Assay Submitted for FDA Clearance SAN DIEGO, July 7 /PRNewswire-FirstCall/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), announced today the CE marking of the BD GeneOhm(TM) Cdiff molecular assay for the rapid diagnosis of patie...

Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections

Company's Next-Generation Cephalosporin Effective Against Difficult-to-Treat Skin Infections, Including Those with methicillin-resistant Staphylococcus aureus (MRSA) NEW YORK, June 19 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) today announced posi...

Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections

Data Presented at the European Cystic Fibrosis Society Conference MONMOUTH JUNCTION, N.J., June 13 /PRNewswire/ -- Transave, Inc., today reported positive results from a Phase II clinical trial on its lead investigational drug, Arikace(TM) (liposomal amikacin for inhalation). The compound i...

Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital-Acquired Infections

Dr. Alan Greenspan, Top Health Care Authorities Discuss Clinical, Financial and Operational Solutions to Growing Patient Safety Issue DUBLIN, Ohio, June 4 /PRNewswire-FirstCall/ -- In a move that reflects its continued commitment to fighting the spread and impact of hospital-acquired infec...

Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections

ASHBURN, Va., April 30 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last of three planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the treatmen...

April 16th Congressional Hearing on Hospital Infections

NEW YORK, April 15 /PRNewswire-USNewswire/ --Tomorrow Congress will hold hearings on whether the federal government is doing enough to prevent deadly hospital infections. The answer is "no." The biggest culprit is the CDC. The CDC claims 1.7 million people contract infections in U.S. hospitals...

Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections

ASHBURN, Va., Feb. 19 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the second of two phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the p...

Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections

Data Shows Excellent Safety Profile and Long Lasting Immunity MCLEAN, Va., and BUDAPEST, Hungary, Feb. 11 /PRNewswire/ -- Genetic Immunity, a US/Hungarian clinical-stage biopharmaceutical company focusing on the development of its patented immunotherapeutic platform technology, announced ...

Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections

BOSTON, Oct. 25 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. announced today that it has closed the first tranche of a $40 million private financing. Aisling Capital led the round, with additional participation by new investors, D.E. Shaw and Boston Life Science Venture Corporation, and curre...

VA National Campaign Takes Aim at Resistant Staph Infections

VA Medical Facilities Leaders in Fight Against MRSA WASHINGTON, Oct. 18 /PRNewswire-USNewswire/ -- Building on the success of a pilot program that reduced a worrisome staph infection by 50 percent, the Department of Veterans Affairs (VA) has tough new screening requirements now in place in a...